Lars Abrahmsen Biography and Net Worth

SVP of Aprea Therapeutics

Lars Abrahmsen, Ph.D. has served as our Senior Vice President, Chief Scientific Officer since October 2014. Dr. Abrahmsen has more than 30 years of experience in research and drug development in the pharmaceutical industry, both with small molecules and biopharmaceuticals. Beginning with postdoctoral work at Genentech, he has also worked at Biovitrum, Pharmacia&Upjohn, Pharmacia and KabiGen. More recently he served as Chief Scientific Officer at Affibody from 2004-2010 and as SVP of Protein Therapeutics at Algeta from 2010-2013. Dr. Abrahmsen has experience from discovery research to preclinical development and has primarily focused on projects within oncology and metabolic diseases. Dr. Abrahmsen received a Ph.D. in Biochemistry and an M.S. in Chemistry, both from the Royal Institute of Technology in Stockholm, Sweden.

How old is Lars B. Abrahmsen?: Dr. Abrahmsen is currently 67 years old. There are 4 older executives and no younger executives at Aprea Therapeutics. Learn More on Lars B. Abrahmsen's age.
How do I contact Lars B. Abrahmsen?: The corporate mailing address for Dr. Abrahmsen and other Aprea Therapeutics executives is 535 BOYLSTON STREET, BOSTON MA, 02116. Aprea Therapeutics can also be reached via phone at 617-463-9385 and via email at [email protected]. Learn More on Lars B. Abrahmsen's contact information.
Has Lars B. Abrahmsen been buying or selling shares of Aprea Therapeutics?: Lars B. Abrahmsen has not been actively trading shares of Aprea Therapeutics within the last three months. Most recently, Lars B. Abrahmsen sold 2,500 shares of the business's stock in a transaction on Friday, October 1st. The shares were sold at an average price of $97.80, for a transaction totalling $244,500.00. Learn More on Lars B. Abrahmsen's trading history.
Who are Aprea Therapeutics' active insiders?: Aprea Therapeutics' insider roster includes Lars Abrahmsen (SVP), Eyal Attar (SVP), and Gregory Korbel (SVP). Learn More on Aprea Therapeutics' active insiders.
Are insiders buying or selling shares of Aprea Therapeutics?: In the last year, Aprea Therapeutics insiders bought shares 10 times. They purchased a total of 52,160 shares worth more than $237,048.00. In the last year, insiders at the sold shares 1 times. They sold a total of 6,462 shares worth more than $29,595.96. The most recent insider tranaction occured on October, 23rd when CEO Oren Gilad bought 500 shares worth more than $1,960.00. Insiders at Aprea Therapeutics own 12.8% of the company. Learn More about insider trades at Aprea Therapeutics.
Information on this page was last updated on 10/23/2024.

Lars B. Abrahmsen Insider Trading History at Aprea Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/1/2021	Sell	2,500	$97.80	$244,500.00

Lars B. Abrahmsen Buying and Selling Activity at Aprea Therapeutics

Aprea Therapeutics Company Overview

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Today's Range

Now: $2.92

$2.90

$3.00

50 Day Range

MA: $3.31

$2.54

$4.45

2 Week Range

Now: $2.92

$2.15

$8.85

Volume

4,328 shs

Average Volume

20,160 shs

Market Capitalization

$15.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97

Watch this before it gets removed

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.